Galangin and Pinocembrin from Propolis Ameliorate Insulin Resistance in HepG2 Cells via Regulating Akt/mTOR Signaling
-
- Yinkang Liu
- Institute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China
-
- Xiali Liang
- Institute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China
-
- Gensheng Zhang
- College of Food Engineering, Harbin University of Commerce, Harbin 150076, China
-
- Lingjie Kong
- Institute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China
-
- Wenjun Peng
- Institute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China
-
- Hongcheng Zhang
- Institute of Apicultural Research, Chinese Academy of Agricultural Sciences, Beijing 100093, China
Description
<jats:p>Insulin resistance has a critical role in type 2 diabetes. The aim of this study was to investigate the effect of pinobanksin, galangin, chrysin, and pinocembrin from propolis on insulin resistance. Our study shows that galangin and pinocembrin can ameliorate insulin resistance; on the contrary, pinobanksin and chrysin are ineffective. Galangin and pinocembrin treatments substantially increase glucose consumption and glycogen content by enhancing the activities of hexokinase and pyruvate kinase. Galangin treatment with 80 <jats:italic>μ</jats:italic>M increased hexokinase and pyruvate kinase activities by 21.94% and 29.12%, respectively. Moreover, we hypothesize that galangin and pinocembrin may have a synergistic effect on the improvement of insulin resistance via Akt/mTOR signaling pathway, through distinctly upregulating the phosphorylation of IR, Akt, and GSK3<jats:italic>β</jats:italic> and remarkably downregulating the phosphorylation of IRS. Most notably, this is the first study to our knowledge to investigate pinocembrin about the alleviation of insulin resistance. Our results provide compelling evidence for the depth development of propolis products to ameliorate insulin resistance.</jats:p>
Journal
-
- Evidence-Based Complementary and Alternative Medicine
-
Evidence-Based Complementary and Alternative Medicine 2018 1-10, 2018-10-21
Hindawi Limited
- Tweet
Details 詳細情報について
-
- CRID
- 1363951794943719424
-
- ISSN
- 17414288
- 1741427X
-
- Data Source
-
- Crossref